What is United Therapeutics' stock symbol?
United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."
Where is United Therapeutics' stock going? Where will United Therapeutics' stock price be in 2017?
12 brokerages have issued 1 year price objectives for United Therapeutics' shares. Their predictions range from $95.00 to $229.00. On average, they anticipate United Therapeutics' share price to reach $134.18 in the next year.
When will United Therapeutics announce their earnings?
United Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.
What are analysts saying about United Therapeutics stock?
Here are some recent quotes from research analysts about United Therapeutics stock:
According to Zacks Investment Research, "United Therapeutics holds a strong position in the pulmonary arterial hypertension (PAH) market with four approved products targeting this indication. The company’s latest PAH offering, Orenitram, should continue to witness higher sales on the back of new patient starts, increasing patient referrals, and higher uptake in community centers. United Therapeutics’ shares outperformed the Drugs industry in the past one year. Meanwhile, we believe the company needs to use cash suitably to deal with generic competition for flagship product Remodulin that could materialize post Oct 2017 and work on expanding its portfolio. Nonetheless, the company is working on new delivery mechanisms and indications for its marketed products which might drive long-term growth. Estimates for 2017 have moved up lately ahead of Q4 earnings release. The company has a positive record of earnings surprises in recent quarters." (1/17/2017)
Jefferies Group LLC analysts commented, "Despite the impact seen in 2Q from competitor Uptravi, UTHR is confident of a rebound in Tyvaso/Orenitram sales going forward, citing waning Uptravi warehousing effect." However, we continue to be cautious on Uptravi competition & upcoming patent expiry (Remodulin generic entry beginning in mid-2018); we project a revenue CAGR of (5%) for 2015-2020. Approx. 5% higher 2Q16 revenue of ~$413M (vs. ours/cons $392M/$395M) driven by Remodulin & Adcirca (Chart 1). Approx. 3% higher treprostinil franchise sales included ~10%/9% higher Remodulin sales of $159M (vs. ours/cons $144M/$146M) likely due to variations in timing & magnitude of specialty distributors’ orders, flat/5% lower Tyvaso sales of $107M (vs. ours/cons $107M/$113M) despite a ~5% price increase on 4/30/16; & ~16%/12% lower Orenitram sales of $38M (vs. ours/cons $45M/$43M). UTHR attributed ~15%/21% higher Adcirca sales of ~$91M (vs." (7/29/2016)
Who owns United Therapeutics stock?
United Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (9.53%), Palo Alto Investors LLC (4.41%), State Street Corp (4.38%), AQR Capital Management LLC (3.20%), Thompson Siegel & Walmsley LLC (1.22%) and Dimensional Fund Advisors LP (1.06%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, David Zaccardelli, Louis W Sullivan, Martine A Rothblatt, Paul A Mahon, Ray Kurzweil, Raymond Dwek, Richard Giltner, Roger Jeffs and Tommy G Thompson.
Who sold United Therapeutics stock? Who is selling United Therapeutics stock?
United Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Oxford Asset Management, State Street Corp, Two Sigma Investments LP, Guggenheim Capital LLC, Federated Investors Inc. PA, Asset Management One Co. Ltd. and Thompson Siegel & Walmsley LLC. Company insiders that have sold United Therapeutics stock in the last year include Christopher Patusky, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson.
Who bought United Therapeutics stock? Who is buying United Therapeutics stock?
United Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Dimensional Fund Advisors LP, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main, Palo Alto Investors LLC, Frontier Capital Management Co. LLC, Flinton Capital Management LLC, Tyers Asset Management LLC and Renaissance Technologies LLC.
How do I buy United Therapeutics stock?
Shares of United Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of United Therapeutics stock cost?
One share of United Therapeutics stock can currently be purchased for approximately $167.92.